NCT03488693

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2018-10-16Est. Completion: 2027-09-01

Enrollment target: 2,140 participants

Locations

Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Banner-University Medical Center Phoenix, Phoenix, Arizona, United States
University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Kaiser Permanente-Anaheim, Anaheim, California, United States
Kaiser Permanente-Bellflower, Bellflower, California, United States
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
City of Hope Corona, Corona, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Kaiser Permanente Dublin, Dublin, California, United States
UC San Diego Health System - Encinitas, Encinitas, California, United States
Fresno Cancer Center, Fresno, California, United States
City of Hope at Irvine Lennar, Irvine, California, United States

Other microbiome trials you might be interested in

Breast Phyllodes Tumors: Based on 20-year Real-world Data From ChinaCompleted

Phyllodes Breast TumorPrognosis

Phyllodes tumor (PT) is a rare type of breast tumor made up of both connective tissue (stroma) and gland tissue (epithel…

Guangzhou, ChinaCompleted May 1, 2026

View Trial →

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 2Recruiting

Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.